Which statement accurately reflects first-line pharmacologic treatment for GAD?

Which statement accurately reflects first-line pharmacologic treatment for GAD?

• A. SSRIs and SNRIs are first-line; benzodiazepines are not.
• B. Benzodiazepines are first-line.
• C. Monoamine oxidase inhibitors are first-line.
• D. Antipsychotics are first-line.

Answer: (D)

The main idea here is that first-line pharmacologic treatment for generalized anxiety disorder is an antidepressant from the SSRI or SNRI class. These medications have the strongest overall evidence for reducing chronic anxiety symptoms and tend to have a more favorable safety profile for long-term use compared with other options. Examples include SSRIs such as sertraline, escitalopram, and paroxetine, and SNRIs such as venlafaxine and duloxetine. They typically take several weeks to achieve full benefit, so patients need reassurance about the delay and a plan for monitoring symptoms during that period. Benzodiazepines can provide rapid anxiety relief, but they carry risks of dependence, tolerance, and withdrawal, and they don’t treat the underlying anxiety long-term, so they aren’t considered first-line for GAD. Monoamine oxidase inhibitors are not first-line due to their difficult dietary restrictions, drug interactions, and more challenging side-effect profile, making them less desirable as initial therapy. Antipsychotics are not first-line for GAD; they’re not indicated for initial treatment of generalized anxiety and carry risks of metabolic effects and other side effects, though they may be considered in certain complex or comorbid cases under specialist care. So, the take-home is: SSRIs and SNRIs are the preferred starting pharmacologic treatment for GAD, with benzodiazepines reserved for short-term use in specific circumstances, and MAO inhibitors or antipsychotics not used as first-line.

The main idea here is that first-line pharmacologic treatment for generalized anxiety disorder is an antidepressant from the SSRI or SNRI class. These medications have the strongest overall evidence for reducing chronic anxiety symptoms and tend to have a more favorable safety profile for long-term use compared with other options. Examples include SSRIs such as sertraline, escitalopram, and paroxetine, and SNRIs such as venlafaxine and duloxetine. They typically take several weeks to achieve full benefit, so patients need reassurance about the delay and a plan for monitoring symptoms during that period.

Benzodiazepines can provide rapid anxiety relief, but they carry risks of dependence, tolerance, and withdrawal, and they don’t treat the underlying anxiety long-term, so they aren’t considered first-line for GAD.

Monoamine oxidase inhibitors are not first-line due to their difficult dietary restrictions, drug interactions, and more challenging side-effect profile, making them less desirable as initial therapy.

Antipsychotics are not first-line for GAD; they’re not indicated for initial treatment of generalized anxiety and carry risks of metabolic effects and other side effects, though they may be considered in certain complex or comorbid cases under specialist care.

So, the take-home is: SSRIs and SNRIs are the preferred starting pharmacologic treatment for GAD, with benzodiazepines reserved for short-term use in specific circumstances, and MAO inhibitors or antipsychotics not used as first-line.